TABLE 2.
Patient demographics
| Subjects | 50 |
| Age years | 62.20±13.47 |
| Male | 30 (57.69) |
| Living arrangement | |
| Living alone | 9 (20.93) |
| Living with spouse/family | 34 (79.07) |
| Employment status | |
| Retired | 26 (57.78) |
| Not working for medical reasons | 7 (15.56) |
| Working (full- or part-time) | 12 (26.67) |
| Age of asthma diagnosis years | 23.60±21.45 |
| ACQ score | 2.01±1.27 |
| Exacerbations in past year | 3.00 (2–5) |
| Maintenance OCS prescription | 19 (38) |
| OCS daily dose mg | 7.00 (5.00–25.00) |
| ICS daily dose beclomethasone equivalent units | 2000 (1000–2000) |
| Add-on severe asthma medication | 41 (82) |
| Azithromycin | 11¶ (22) |
| Mepolizumab | 27 (54) |
| Omalizumab | 10 (20) |
| Benralizumab | 3 (6) |
| Teplizumab# | 1 (2) |
| No add-on therapy | 9 (18) |
| Months of monoclonal antibody therapy | 7 (3–24) |
Data are presented as n, n (%), mean±sd or median (interquartile range). ACQ: asthma control questionnaire; IQR: interquartile range; OCS: oral corticosteroid; ICS: inhaled corticosteroid. #: one participant was on a clinical trial of teplizumab in the survey group; ¶: azithromycin was an add-on therapy to the monoclonal medications in all but one participant.